Does NCT06868277 meet its primary endpoint at primary completion?

80% likely to miss · raimo

target TIGIT · moa checkpoint-inhibition · failure mode target-redundant

1. premise rilvegostomig is a PD-1xTIGIT bispecific; vs pembrolizumab its only differentiator is TIGIT blockade, on the same immune-synapse axis PD-1 already addresses
2. premise anti-TIGIT on a PD-(L)1 backbone failed to improve outcomes in the SKYSCRAPER-01 phase 3 resolved_trial:NCT04294810
3. inference TIGIT is target-redundant against the backbone in 1L NSCLC
4. prediction no OS superiority over pembrolizumab; primary endpoint not met

Evidence: resolved_trial:NCT04294810